FDA Grants Priority Review to uniQure Huntington’s Gene-Therapy Application

FDA accepted uniQure’s AMT-130 application for Priority Review, with a May 1, 2027 target decision. The application relies on a 36-month comparison with an external control, while a randomized confirmatory trial is planned; review acceptance does not establish benefit, and prior evidence reports have raised doubts about slowing progression.